Influenza Medications Market - Drug Type (Antiviral [Single, Combination], Antihistamines), Influenza Type (A, B), Age Group, Route of Administration (Oral, Inhaled), Type (Branded, Generic), Medication, Distribution Channel, Global Forecast (2024 – 2032)

Influenza Medications Market Size

Influenza Medications Market size was valued at USD 942.6 million in 2023 and is anticipated to witness 2.9% CAGR from 2024-2032, driven by the rising prevalence of influenza. As per WHO, there are 3 to 5 million cases of severe illness and between 290,000 to 650,000 respiratory deaths each year. Pharmaceutical companies are investing in new antagonists with unique mechanisms against influenza viruses. Advanced influenza testing, including rapid influenza test, is helping facilitate early diagnosis and treatment.
 

The aging population worldwide, which is more susceptible to severe influenza, will further propel the demand for these medications. Government policies and public health campaigns are helping in improving vaccination and preparedness for influenza pandemics. Rising healthcare costs and expanded healthcare coverage in emerging markets are also contributing to the market expansion.

However, the rapid mutation of influenza viruses may continue to pose a hurdle, as it can render existing drugs as less effective whilst requiring constant updating of therapeutic protocols. The availability and reliance on seasonal influenza vaccination will also reduce the demand for antiviral drugs. Regulatory hurdles and complicated approval processes can delay the introduction of new treatments. Limited access to healthcare facilities in low-income areas and lack of awareness among some people about the availability of antibiotics are hampering the industry expansion.
 

Influenza Medications Market Trends

With the rising number of influenza cases, there is a higher demand for drugs to treat and prevent the illness. Health professionals and the public are increasingly aware of the importance of early diagnosis and treatment of influenza. The availability of effective treatments, such as antibiotics has increased the acceptance of influenza vaccines by health care providers and patients. To that end, many individuals are seeking treatment for influenza symptoms, leading to increased market growth.

Pharmaceutical companies and research institutions are further actively involved in R&D activities aimed at discovering and developing new influenza drugs. These efforts are driven by the necessity to address challenges, such as antiviral resistance, limited treatment options, and the potential for future influenza pandemics.
 

Influenza Medications Market Analysis

The market based on drug type is bifurcated into antiviral drugs, antihistamines, analgesics, and antipyretics. The antiviral drugs segment generated USD 520.3 million in 2023 and will witness growth at 3.4% CAGR during 2024-2032. Antibiotics are considered the mainstay of treatment for influenza infections. These are important in the management and treatment of influenza, as their direct aim is to reduce the severity and duration of viral infection. The effectiveness in the treatment of influenza has led to their widespread use, especially during influenza season.  Moreover, improved development of new antiviral drugs and better safety profile have further enhanced the product uptake.
 

Based on influenza type, the influenza medications market size from the influenza A segment was valued at over USD 704 million in 2023 and is expected to reach USD 897.4 million by 2032. Influenza A viruses are responsible for most influenza outbreaks at times and can cause severe illness compared to influenza B viruses. This virus circulates extensively and is known to cause significant morbidity and mortality, resulting in increased demand for influenza A vaccines and prevention. The widespread accessibility and prescription of antiviral drugs and the rising usage of influenza vaccines to prevent influenza A will contribute to the segment growth.
 

In terms of age group, the influenza medications market from the adults segment is expected to depict 3% CAGR from 2024 – 2032. Adults usually experience higher rates of influenza incidence compared to pediatric and geriatric populations. They are exposed to influenza viruses in social settings, workplaces, and public spaces, leading to increased susceptibility to infection. They also experience severe symptoms compared to children, subsequently requiring more intensive medication and care. Thus, the higher incidence rates along with increased severity of the disorder will drive significant demand for influenza medications among adults.
 

Based on type, the influenza medications market from the branded segment was valued at USD 755 million in 2023. Branded products are often associated with established pharmaceutical companies with a reputation for quality, efficacy, and safety. These drugs typically result from extensive R&D efforts, including preclinical studies, clinical trials, and regulatory approvals. Additionally, healthcare professionals frequently prescribe branded medicines, contributing to the segment growth.

Based on route of administration, the oral segment is expected to reach over USD 1 billion by 2032. The oral route facilitates dose adjustment and convenience, making it suitable for a wide range of patients, including children and the elderly. Moreover, oral medications tend to be more cost-effective compared to other delivery methods, such as intravenous or inhaled drugs, due to lower manufacturing and delivery costs. This affordability is making these medications attractive to patients and healthcare systems.  

Influenza medications market from the prescription medication segment was valued at USD 708.9 million in 2023 and will strike a 2.6% CAGR through 2032. Prescription drugs are more potent and specific in targeting the influenza virus, making them more effective compared to alternatives.  The potential for severe complications from influenza, particularly in high-risk populations, such as the elderly, young children and individuals with underlying health conditions will drive the demand for potential prescription drugs for providing effective treatment and reduced risk of complications. The dominance of prescription drugs to support the health system and ensure optimal outcomes for patients will favor the product uptake.

Based on distribution channel, the influenza medications market value from the hospital pharmacies segment is predicted to generate USD 619.7 million by 2032. Hospitals serve as the primary point for patient care with a high volume of patients compared to other healthcare settings for catering to a greater demand for influenza medications. Hospital pharmacies are staffed by druggists with clinical expertise who work closely with healthcare providers to assure accurate and safe medication management for individuals. The strict regulation and control over the distribution and usage of drugs is also making these channels the preferred and regulated source for these medications.

North America influenza medications market size may reach USD 548.7 million by 2032 attributed to the significant burden of influenza infections annually. Factors, such as population density, international travel, and seasonal variations are contributing to the widespread transmission of influenza viruses, leading to a high demand for influenza medicines. The well-developed healthcare infrastructure with advanced medical facilities, including clinics, hospitals, and pharmacies will further propel the regional market growth.  
 

Influenza Medications Market Share

The influenza medications industry is characterized by the existence of several key players competing to meet the demand for effective treatments and preventive measures against influenza. The market players are continuously involved in innovation, collaboration, and new product launches to maintain a competitive edge in the market.
 

Influenza Medications Market Companies

Leading firms operating in the influenza medications industry include:

• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd
• BioCryst Pharmaceuticals, Inc.
• Sanofi
• Daiichi Sankyo Company
• Novartis AG
• F. Hoffmann-La Roche AG
• NATCO Pharma Limited
• GlaxoSmithKline plc
• Lupin
   

Influenza Medications Industry News

• In August 2022, Genetech announced the U.S. FDA approval of Xofluza to treat influenza in children aged 5 years and older, helping the company to strengthen its product portfolio and increase their revenue.
   
• In August 2022, Roche announced the approval of a supplemental New Drug Application (sNDA) for Xofluza, providing the company with significant opportunities for market expansion and enhance its product portfolio.
   

The influenza medications market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Antiviral drugs
  • Single antiviral drugs
  • Combination antiviral drugs
• Antihistamines
• Analgesics
• Antipyretics

Market, By Influenza Type

• Influenza A
• Influenza B

Market, By Age Group

• Adults
• Pediatric
• Geriatric

Market, By Route of Administration

• Oral
• Inhaled
• Intravenous

Market, By Type

• Branded
• Generic

Market, By Medication

• Prescription
• OTC

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa